5-(p-Methoxyphenyl)-4-methyl-1,2-dithiole-3-thione | 65490-84-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-(p-Methoxyphenyl)-4-methyl-1,2-dithiole-3-thione
• 英文别名: 5-(4-methoxy-phenyl)-4-methyl-[1,2]dithiol-3-thione；5-(4-Methoxy-phenyl)-4-methyl-[1,2]dithiol-3-thion；ADT；4-Methyl-5-(4-methoxyphenyl)-1,2-dithiole-3-thio；5-(4-methoxyphenyl)-4-methyldithiole-3-thione
• CAS: 65490-84-8
• 化学式: C₁₁H₁₀OS₃
• 分子量: 254.398
• InChiKey: BIISXCBJKYLRNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  91.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  p-甲氧基异苯丁酮 在 联苯 、 phosphorous (V) sulfide 、 sulfur 作用下， 生成 5-(p-Methoxyphenyl)-4-methyl-1,2-dithiole-3-thione
  参考文献：
  名称：

  Legrand; Lozac'h, Bulletin de la Societe Chimique de France, 1956, p. 1130,1133

  摘要：

  DOI：

文献信息

• Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
  申请人：CENTRE HOSPITALIER UNIVERSITAIRE DE BOURDEAUX

  公开号：US10272066B2

  公开（公告）日：2019-04-30

  The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.

  本发明涉及使用化合物预防和治疗疾病，这些疾病的起因和/或演变与线粒体活性氧（ROS）的产生和影响有关。
• Flavopiridol drug combinations and methods with reduced side effects
  申请人：——

  公开号：US20020016293A1

  公开（公告）日：2002-02-07

  This invention provides methods, formulations and kits to reduce the toxicity of flavopiridol and analogs thereof. Disclosed are therapeutics and treatment methods employing such drugs in combination with agents that increase conjugative enzyme activity or glucuronosyltransferase activity, and agents that decrease biliary transport protein activity, such as cyclosporine A, the resultant effects of which are to decrease the significant side effects previously associated with treatment using these drugs. The invention also characterizes specific isoforms of glucuronyltransferase enzymes involved in glucuronidation of flavopiridols and their analogs.

  本发明提供了降低黄连素及其类似物毒性的方法、制剂和试剂盒。本发明公开了采用这类药物与增加共轭酶活性或葡萄糖醛酸基转移酶活性的药剂和降低胆汁转运蛋白活性的药剂（如环孢素 A）联合使用的治疗方法和治疗方法，其结果是减少了以前使用这类药物治疗时的显著副作用。本发明还描述了参与黄烷醇及其类似物葡萄糖醛酸化的葡萄糖醛酸转移酶的特异异构体。
• CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS
  申请人：ARCH DEVELOPMENT CORPORATION

  公开号：EP0768895A1

  公开（公告）日：1997-04-23
• Compositions and methods for modulating the immune system
  申请人：Prendergast Patrick T.

  公开号：US20090156546A1

  公开（公告）日：2009-06-18

  The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.
• COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS
  申请人：Prendergast Patrick T.

  公开号：US20100092547A1

  公开（公告）日：2010-04-15

  A method for prophylaxis and/or treatment of mucositis comprising the steps of providing a therapeutically effective amount of a composition comprising either (1) at least one compound selected from the group consisting of 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; or (2) a cytokinin compound; and administering the composition to a subject in need of such treatment. Also provided are pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione and/or a cytokinin compound and use of these compositions in the preparation of a medicament for the treatment and/or prophylaxis of mucositis. The cytokinin compound may be selected from, but is not limited to N 6 -isopentenyl adenosine and N 6 -benzyl adenosine. The compositions may further comprise a chemotherapeutic agent, such as cisplatin. Further provided are methods and compositions for reducing and/or preventing weight loss in subjects undergoing cancer treatment.